Stock comparison
ELI LILLY & Co is 4.0x more valuable than AstraZeneca PLC by market capitalization ($1.142 T vs $286.27 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
LLY is larger
ELI LILLY & Co is 4.0x more valuable than AstraZeneca PLC by market capitalization ($1.142 T vs $286.27 B).
Market value leader
LLY
ELI LILLY & Co is 4.0x more valuable than AstraZeneca PLC by market capitalization ($1.142 T vs $286.27 B).
| Metric | LLY | AZN |
|---|---|---|
| Market cap | $1.142 T | $286.27 B |
| US-listed rank | #10 | #50 |
| Revenue (latest FY) | $65.18B | - |
| Net income (latest FY) | $20.64B | - |
| Net margin | 31.7% | - |
| P/E (trailing FY) | 55.3x | - |
| SEC filings | 995 | 1,004 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
ELI LILLY & Co is 4.0x more valuable than AstraZeneca PLC by market capitalization ($1.142 T vs $286.27 B).
Full pages: ELI LILLY & Co and AstraZeneca PLC, or browse the full rankings.